Merck & Co, Inc NYSE:MRK announced today that following a pre-specified interim analysis from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus infection, the independent Data Monitoring Committee (DMC) recommended suspension of enrollment.

Even though the trial did not meet the pre-specified futility criteria, the DMC nonetheless recommended suspension of enrollment pending further analyses of the benefit/risk profile of the vaccine candidate.

Merck & Co, Inc NYSE:MRK on April 08, 2011 increased 1.02% with the closing price of $33.67. The overall volume in the last trading session was 18.39 million shares. Its fifty two week range was $30.70-$37.68. The total market capitalization remained $103.81 billion.

The MRK share price is moving forward from its 52 week low price by 14.55% and going below from its 52 week high price with 9.45%. In the current year its quarter performance included -8.80% while company’s current year earnings per share decreased by 95.13%. The MRK stock price is moving forward from its 20 days moving average with 3.29% and it is going above from its 50 days moving average with 3.40%.

MRK has its stock institutional ownership remained 74.61% while its insider ownership included 0.03%. In its share capital MRK has 3.08 billion shares outstanding and among them approximately 3.05 billion shares have been floated in market exchange while the last month share price volatility included 1.12%. Company’s market risk identifying beta coefficient recorded 0.70. Beta coefficient is a measure that identifies the market risk associated with the trading.

Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through its prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, company works with customers and operates in more than 140 countries to deliver innovative health solutions. Merck also demonstrates its commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. galaxystocks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://galaxystocks.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold galaxystocks.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.